Resolution of Persistent Cystoid Macular Edema due to Central Retinal Vein Occlusion in a Vitrectomized Eye following Intravitreal Implant of Dexamethasone 0.7 mg
Autor: | Vittorio Grande De, Marco Zagari, Michele Reibaldi, Valentina Cifalinò, Stefania Rametta, Andrea Russo, Antonio Longo, Mario Damiano Toro, Salvatore Faro |
---|---|
Přispěvatelé: | Reibaldi, M, Russo, A, Zagari, M, Toro, M, Grande De, V, Cifalinò, V, Rametta, S, Faro, S, Longo, A. |
Jazyk: | angličtina |
Rok vydání: | 2012 |
Předmět: |
medicine.medical_specialty
Visual acuity genetic structures Bevacizumab medicine.medical_treatment Dexamethasone 0.7 mg Vitrectomy Published: January 2012 lcsh:Ophthalmology Central retinal vein occlusion medicine Dexamethasone Intravitreal Implant Macular edema Dexamethasone business.industry Ozurdex® medicine.disease eye diseases Surgery Ophthalmology lcsh:RE1-994 Vitreous hemorrhage Vitrectomized eye sense organs medicine.symptom business Cystoid macular edema medicine.drug |
Zdroj: | Case Reports in Ophthalmology, Vol 3, Iss 1, Pp 30-34 (2012) Case Reports in Ophthalmology |
Popis: | We report the case of a 62-year-old woman with a history of vitreoretinal surgery for vitreous hemorrhage secondary to central retinal vein occlusion (CRVO). Because of the persistence of macular edema (ME), she received 2 intravitreal injections of bevacizumab 0.5 mg (Avastin®, Genentech/Roche) three months after vitrectomy, without functional or anatomical improvement. Six months after vitrectomy, she therefore received an intravitreal implant of dexamethasone 0.7 mg (Ozurdex®). An improvement in her best-corrected visual acuity and central macular thickness, as measured by optical coherence tomography, was detected 7 days after the injection, and complete resolution of the ME and retinal hemorrhages was observed 6 months after the injection. Dexamethasone intravitreal implant might be an effective treatment option in ME secondary to CRVO, also in vitrectomized eyes. |
Databáze: | OpenAIRE |
Externí odkaz: |